{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-22-016735","form_type":"8-K","ticker":"ACRS","cik":"0001557746","company_name":"Aclaris Therapeutics, Inc.","filed_at":"2022-11-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:51.139487+00:00","generated_at":"2026-06-22T03:34:51.056642+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Aclaris Q3 net loss $20M, revenue $19M on $17.6M Lilly license; ATI-2138 Phase 1 SAD positive","bullets":["Net loss of $20.0M for Q3 2022 vs $21.1M in Q3 2021; operating loss offset by $17.6M licensing revenue from Lilly alopecia areata patent deal.","Total revenue of $19.0M, up from $1.7M year-over-year, driven by $17.9M licensing revenue.","Cash, equivalents and marketable securities of $248.1M as of Sep 30, 2022; sufficient to fund operations through end of 2025.","Phase 2a enrollment completed for zunsemetinib in hidradenitis suppurativa (95 patients); topline data expected mid-first half 2023.","ATI-2138 Phase 1 SAD trial completed; generally well-tolerated, dose-dependent ITK/JAK3 inhibition; ulcerative colitis selected as first target; new IND submitted."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-22-016735","json":"https://secwatch.observer/filing/0001558370-22-016735.json","markdown":"https://secwatch.observer/filing/0001558370-22-016735.md","text":"https://secwatch.observer/filing/0001558370-22-016735.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1557746/000155837022016735/0001558370-22-016735-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1557746/000155837022016735/acrs-20221108x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T03:34:51.056642+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"ae6eff4cb3f7d9a0622a3d806980a5d4ea66a7ec","claim":"Aclaris Therapeutics, Inc. reported financial results for the quarter and nine months ended September 30, 2022.","evidence_excerpt":"On November 8, 2022, Aclaris Therapeutics, Inc. (the “ Registrant ”) issued a press release announcing its financial results for the quarter and nine months ended September 30, 2022","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1557746/000155837022016735/0001558370-22-016735-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter and nine months ended September 30, 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}